Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy
NCT ID: NCT05301790
Last Updated: 2022-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
45 participants
OBSERVATIONAL
2022-05-31
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Breast MRI for Neaodjuvant Chemotherapy Response Prediction and Evaluation in Breast Cancer
NCT03580837
Accuracy Of Contrast Enhanced Mamography in Predicting Response of Breast Cancer Post Neoadjuvant Chemotherapy
NCT05141279
Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer
NCT03592004
Functional MRI in Predicting Response to Chemotherapy
NCT03969524
What Factors Affect Breast Cancer Neoadjuvant Chemotherapy Efficacy?
NCT03501394
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
use of MRI modality of imaging in evaluation of pathologic response in patients with breast cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with locally advanced breast cancer
* Patients with early stage breast cancer and chemo-responsive tumour markers (i.e. triple negative, Her2+), who will benefit from downsizing for breast conserving surgery (BCS)
* Absolute or Relative contraindications to surgery (advanced age/multiple medical comorbidities) in the setting of estrogen receptor positive tumours (for consideration of neoadjuvant endocrine therapy)3
* Patients must be elder than 18 years old.
* patients with accepted renal function
Exclusion Criteria
* Patient with breast mass more than 5 cm .
* Patients with fungating breast mass .
* Patients with stage IV \[tumor spread to chest wall and to skin \].
* pregnant women especially in 1th trimester.
* Patient with presence of any paramagnetic substance as pacemakers.
* severely ill patients .
* patients with claustrophobia.
* arrhythmic patients
18 Years
80 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Doaa Maher Ebied Maher
resident
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
lamiaa mohamed refaat, assisstant professor
Role: STUDY_DIRECTOR
assiut university -south egypt cancer institute
omar mostafa, lecturer
Role: STUDY_DIRECTOR
assiut university-south egypt cancer institute
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MRI in breast cancer
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.